ClinicalTrials.gg
RecruitingNCT05736198Updated Oct 9, 2026

Comparison of Two Sedation Regimens for Awake Fiberoptic Intubation

An observational study in Awake Fiberoptic Intubation and Difficult Airway, sponsored by University of Illinois at Chicago. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by University of Illinois at Chicago · Observational

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
96
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to examine the effects of different sedation drugs used for the awake fiberoptic intubation procedure. Benzodiazapines and narcotics (such as midazolam and fentanyl) are standard drugs used for sedation during awake fiberoptic intubation. Dexmedetomidine, midazolam, and fentanyl are approved by the Food and Drug Administration (FDA) procedural sedation. These drugs might be given to the patient regardless of their participation in the study.

In addition to midazolam and fentanyl study subjects will also receive either dexmedetomidine or a placebo (a salt solution that contains no drug). It is believed that dexmedetomidine will not slow down breathing as much as the combination of the valium-like drug and narcotic. In our study, we are trying to determine if this is the best drug for sedation during an awake fiberoptic procedure.

Read the detailed description

This is an observational study designed to evaluate effectiveness of two standard of care protocols used for patients with potentially difficult airway during awake fiberoptic intubation.

After obtaining informed consent, patients will be randomized into one of two groups. The first group will receive placebo, midazolam, and fentanyl (titrated to effect) to facilitate the intubation. The second group will receive dexmedetomidine, midazolam, and fentanyl (titrated to effect) to facilitate intubation. Both groups will have a transtracheal injection and/or direct topical application of lidocaine to decrease irritation of the trachea and vocal cords.

As the patients in the study all have potentially difficult airways, the usual precautions will be taken to minimize the risks to the patients. These include the availability of alternative airway devices (including LMAs and Intubating LMA systems). Doses of dexmedetomidine will conform to the recommended dosing schedules of between 0.3 and 0.7 mcg/kg/hour.

All the drug stated above are currently FDA approved and are used according to the standard of care.

Patient medical records will be reviewed to determine the amount of fentanyl that was used to facilitate intubation as well as homodynamic stability during the procedure and oxygen saturation. A brief 5-minute survey will be conducted 24 hours after the surgery to access patient satisfaction with intubation procedure. Intubation conditions stated below will be recorded by the anesthesiologist during the procedure.

The intubating conditions (gagging, discomfort of patient, and oxygen saturation) and hemodynamic stability during the procedure will be recorded by the research assistant and the patient's satisfaction with the undertaking (after the surgery is completed) will be determined as well. The amount of fentanyl used to facilitate intubation will also be recorded.

02

Conditions studied

  • Awake Fiberoptic Intubation
  • Difficult Airway

Keywords

  • Dexmedetomidine
03

In context

Lead sponsor

University of Illinois at Chicago is the lead sponsor of 496 studies on the registry; 115 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All adults with potentially difficult airways undergoing elective procedures will be eligible.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with potentially difficult airways who require awake fiberoptic intubations will be identified from the OR schedule and the pre-operative clinic workups.

Exclusion criteria

Exclusion Criteria:

  • Anyone who does not meet the inclusion criteria
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
96 participants (estimated)
Patient registry
No

Groups and cohorts

  • Dexmedetomidine

    Dexmedetomidine, midazolam, and fentanyl (titrated to effect) to facilitate intubation

    Drug: Dexmedetomidine

  • Placebo

    Normal Saline, midazolam, and fentanyl (titrated to effect) to facilitate the intubation

Interventions

  • dexmedetomidine, midazolam, and fentanyl (titrated to effect) to facilitate intubation

    Also known as: Precedex

06

What researchers measure

Primary outcomes

  1. Desaturation

    Measurement using pulse oximetry (percent saturation)

    Time frame: During intubation

  2. Hemodynamic Lability

    mm Hg

    Time frame: During intubation

  3. Dose of Fentanyl Used

    mcg

    Time frame: During intubation

Secondary outcomes

  1. Patient overall experience assessed by VAS satisfaction.

    Polling will be taken to measure patients' satisfaction with each sedation regiment on the scale from 1-10

    Time frame: 24 hours after the surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Scher CS, Gitlin MC. Dexmedetomidine and low-dose ketamine provide adequate sedation for awake fibreoptic intubation. Can J Anaesth. 2003 Jun-Jul;50(6):607-10. doi: 10.1007/BF03018650. PubMed 12826556 ↗

Individual participant data

Plan to share: No — Data will only be shared with study investigators

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2024 (actual). Primary completion is estimated for Jun 2033, 106 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2023
First posted
Feb 21, 2023
StartActual
Aug 12, 2024
Primary completionEst.
Jun 15, 2033
CompletionEst.
Mar 1, 2034
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: index terms and verification date
1 update, last Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Minor edits only
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05736198
Responsible party
David Glick (Department of Anesthesiology Head, University of Illinois at Chicago) — Principal investigator
First posted
Feb 21, 2023
Start date
Aug 12, 2024
Primary completion
Jun 15, 2033 (estimated)
Completion
Mar 1, 2034 (estimated)
Last update
Oct 9, 2026

Study contacts

Alexandra Barabanova, MS
Contact
barabano@uic.edu
(312)355-5733
David Glick, MD
principal investigator · Department of Anesthesiology Head

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion